OC-37: ANTIOXIDANT THERAPY IN HUMAN IMMUNO-DEFICIENCY VIRUS–INFECTION

J Pharm Pharmacogn Res 3(suppl. 1): S55, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-37: ANTIOXIDANT THERAPY IN HUMAN IMMUNO-DEFICIENCY VIRUS–INFECTION

Gil L1, Gravier R1, Tarinas A1, Martínez G2, León OS2.

1Institute of Tropical Medicine “Pedro Kourí” (IPK), Havana, Cuba. E-mail: rosariog@ipk.sld.cu
2Institute of Pharmacy and Food, Havana University, Havana Cuba.

 

Oxidative stress (OS) may play an important role as cofactor in human immunodeficiency virus (HIV) pathogenesis. In populations of HIV-infected patients treated with highly active antiretroviral therapy HAART, the role of OS in disease progression has become more complicated. Whereas HIV itself increases OS levels through replication, control of the virus with HAART may not, as one might expect, reduce oxidative damage levels, as the medications themselves may increase OS. HIV infected individuals is known to be deficient in antioxidant micronutrients that exacerbates de redox status. Antioxidant supplementation may be beneficial in minimizing the co-morbidities associated with these infection, it progression and treatment. The combinations for antioxidants supplementation are diverse as much as controversial the results for efficacy. The option for its use could be an alternative that seeks to both suppresses HIV and restore immune functions with least toxic side effects. At the actual date of HAART´ era we propose the revision about knowledge of oxidative molecular mechanisms involved in disease progression and the use of antioxidants in HIV-seropositive patients with and without HAART.

 

Citation Format: Gil L, Gravier R, Tarinas A, Martínez G, León OS (2015) Antioxidant therapy in human immunodeficiency virus–infection. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S55. Abstract nr OC-37.